 |
| Ingelvac M hyo |
|
| Ingelvac M hyo - an innovative one-shot M hyo vaccine - to provide reliable efficacy from only one dose. |
|
| Powerful formulation |
The unique new adjuvant system in Ingelvac® M.hyo ensures a sustained stimulation of the pig's immune system. The Impran® system utilises a stable water-in-oil emulsion, which delivers antigenic stimulus over a prolonged period of time unlike oil-in-water emulsions used in some other M.hyo vaccines. It's a new formulation that's thicker by design for improved results. And what's more, Ingelvac® M.hyo uses a non-mineral, biodegradable oil, providing excellent local tolerance and improved user safety. |
|
| Improved immuno-stimulation |
| Ingelvac M.hyo provides better humoral and cell-mediated immune response than the current single-shot competitor. |
|
|
| Better immunity than single-shot competitor |
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Days |
|
|
|
29 |
|
|
|
44 |
|
|
|
57 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Ingelvac® M.hyo 1 dose | |
|
|
4.7 |
|
|
|
7.6 |
|
|
|
7.3 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Current single-shot competitor | |
|
|
0 |
|
|
|
0.17 |
|
|
|
3.0 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
|
|
Challenge controls | |
|
|
0.625 |
|
|
|
2.1 |
|
|
|
3.4 |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
||||||||||||||||
|
| Gamma Interferon Stimulation Index (indication of the level of cell mediated immunity). |
|
| And in case you're wondering, Ingelvac® M.hyo also provides protection that is at least as good and often better than two-shot products. Whether M.hyo field challenge is high or low, and even when field infection occurs late in the fattening period, Ingelvac M.hyo still protects through to slaughter. |
|
 |
|
| Protection even when infected late in the fattening period |
| In pigs vaccinated at 3 weeks of age with field infection at 20 weeks of age |
|
|
|||||||||
|
|
|
|
|
|||||
|
|
Vaccine |
|
|
|
Lung lesion score | |
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Ingelvac M.hyo 1 dose | |
|
|
8.5* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Challenge controls | |
|
|
15.2* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
| *like letters are not statistically (p<0.05) different |
|
| Improved weight gain |
| But that's not all. Ingelvac® M.hyo has also been shown to provide improved Average Daily Weight Gain compared with the current single-shot and two-shot competitors. |
|
 |
|
|
|||||||||
|
|
|
|
|
|||||
|
|
Vaccine |
|
|
|
Average Daily Weight Gain in lb/day | |
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Ingelvac M.hyo 1 dose | |
|
|
1.13* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Current single-shot competitor | |
|
|
1.11* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Two-shot competitor | |
|
|
1.09* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
|
|
|
|
|||||
|
|
Challenge controls | |
|
|
0.95* |
|
|
|
|
|
|
|
|
|||||
|
|||||||||
|
| *like letters are not statistically (p<0.05) different |
|
 |
|
| © 2006 Boehringer Ingelheim Ltd UK. All rights reserved. Company Registration Number: 711858 Access to and use of this website is subject to our Terms of use which users are deemed to accept by accessing this website. Any queries concerning the design of the site please send an email to the webmaster. |
|
 |
|
||
|
Effects of depot shots |
|
|
|
|
 |
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||
|
|
|
|
|
|||